Browse

Epigenetic modification is linked to Alzheimer`s disease: is it a maker or a marker?

Cited 32 time in Web of Science Cited 34 time in Scopus
Authors

Lee, Junghee; Ryu, Hoon

Issue Date
2010-10-31
Publisher
KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY
Citation
BMB REPORTS; Vol.43 10; 649-655
Keywords
Alzheimer`s diseaseEpigenetic modificationChromatin remodelingDNA methylation
Abstract
Alzheimer`s disease (AD) is the most common age-dependent neurodegenerative disorder and shows progressive memory loss and cognitive decline. Intraneuronal filaments composed of aggregated hyperphosphorylated tau protein, called neurofibrillary tangles, along with extracellular accumulations of amyloid beta protein (A beta), called senile plaques, are known to be the neuropathological hallmarks of AD. In light of recent studies, epigenetic modification has emerged as one of the pathogenic mechanisms of AD. Epigenetic changes encompass an array of molecular modifications to both DNA and chromatin, including transcription factors and cofactors. In this review, we summarize how DNA methylation and changes to DNA chromatin packaging by post-translational histone modification are involved in AD. In addition, we describe the role of SIRTs, histone deacetylases, and the effect of SIRT-modulating drugs on AD. Lastly, we discuss how amyloid precursor protein (APP) intracellular domain (AICD) regulates neuronal transcription. Our understanding of the epigenomes and transcriptomes of AD may warrant future identification of novel biological markers and beneficial therapeutic targets for AD. [BMB reports 2010; 43(10): 649-655]
ISSN
1976-6696
Language
English
URI
https://hdl.handle.net/10371/78209
DOI
https://doi.org/10.3858/BMBRep.2010.43.10.649
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Medicine (의학과)Journal Papers (저널논문_의학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse